MX391376B - Composiciones de la membrana de la cáscara del huevo para usarse en el tratamiento de la cadena ligera kappa del factor nuclear de las células b activadas (nf-kb) en un organismo hospedero. - Google Patents
Composiciones de la membrana de la cáscara del huevo para usarse en el tratamiento de la cadena ligera kappa del factor nuclear de las células b activadas (nf-kb) en un organismo hospedero.Info
- Publication number
- MX391376B MX391376B MX2017007130A MX2017007130A MX391376B MX 391376 B MX391376 B MX 391376B MX 2017007130 A MX2017007130 A MX 2017007130A MX 2017007130 A MX2017007130 A MX 2017007130A MX 391376 B MX391376 B MX 391376B
- Authority
- MX
- Mexico
- Prior art keywords
- eggshell membrane
- activated
- cells
- nuclear factor
- factor kappa
- Prior art date
Links
- 229940012466 egg shell membrane Drugs 0.000 title abstract 5
- 239000000203 mixture Substances 0.000 title abstract 3
- 230000003213 activating effect Effects 0.000 abstract 1
- 230000004913 activation Effects 0.000 abstract 1
- 210000003719 b-lymphocyte Anatomy 0.000 abstract 1
- 230000008482 dysregulation Effects 0.000 abstract 1
- 239000003623 enhancer Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/57—Birds; Materials from birds, e.g. eggs, feathers, egg white, egg yolk or endothelium corneum gigeriae galli
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Molecular Biology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Neurology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pulmonology (AREA)
- Biomedical Technology (AREA)
- Cardiology (AREA)
- Neurosurgery (AREA)
- Genetics & Genomics (AREA)
- Biotechnology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Meat, Egg Or Seafood Products (AREA)
Abstract
La presente invención se refiere al uso de composiciones de la membrana de la cáscara del huevo para activar los niveles del mejorador de la cadena ligera kappa del factor nuclear de las células B activadas ("NF-kB") en el intestino de un organismo hospedero que lo necesite y a métodos de tratamiento de las afecciones relacionadas con la desregulación de NF-kB. La presente invención proporciona un método para activar NF-kB en el intestino de un organismo hospedero que lo necesite. El método comprende administrar oralmente una cantidad eficaz de una composición que consiste esencialmente de la membrana de la cáscara del huevo, y/o materiales aislados de la membrana de la cáscara del huevo y/o materiales hidrolizados de la membrana de la cáscara del huevo, para la activación de NF-kB con respecto al organismo hospedero.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/US2015/054742 WO2017062016A1 (en) | 2015-10-08 | 2015-10-08 | METHODS FOR TREATING NUCLEAR FACTOR KAPPA-LIGHT-CHAIN-ENHANCER OF ACTIVATED B CELL (NF-ĸB) DYSREGULATION IN A HOST IN NEED THEREOF USING EGGSHELL MEMBRANE COMPOSITIONS |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2017007130A MX2017007130A (es) | 2018-01-30 |
| MX391376B true MX391376B (es) | 2025-03-21 |
Family
ID=58488181
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2017007130A MX391376B (es) | 2015-10-08 | 2015-10-08 | Composiciones de la membrana de la cáscara del huevo para usarse en el tratamiento de la cadena ligera kappa del factor nuclear de las células b activadas (nf-kb) en un organismo hospedero. |
Country Status (16)
| Country | Link |
|---|---|
| US (2) | US10328104B2 (es) |
| EP (1) | EP3359170B1 (es) |
| JP (1) | JP2018531212A (es) |
| KR (1) | KR20180063091A (es) |
| CN (1) | CN107206029A (es) |
| AU (1) | AU2015411324B2 (es) |
| BR (1) | BR112017014304A2 (es) |
| CA (1) | CA2970101A1 (es) |
| DK (1) | DK3359170T3 (es) |
| ES (1) | ES2927890T3 (es) |
| HU (1) | HUE060219T2 (es) |
| MX (1) | MX391376B (es) |
| PL (1) | PL3359170T3 (es) |
| RS (1) | RS63620B1 (es) |
| RU (1) | RU2713656C2 (es) |
| WO (1) | WO2017062016A1 (es) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108991521A (zh) * | 2018-08-10 | 2018-12-14 | 西北农林科技大学 | 一种肠道保护剂及其应用 |
| KR20210052064A (ko) | 2019-10-31 | 2021-05-10 | 강원대학교산학협력단 | 소나무 껍질 추출물을 유효성분으로 함유하는 허혈성 뇌혈관 질환 예방용 조성물 |
| KR102296347B1 (ko) | 2019-11-27 | 2021-09-01 | 강원대학교산학협력단 | 천연물 복합 추출물을 유효성분으로 함유하는 허혈성 뇌혈관 질환 예방용 조성물 |
| CN118272477B (zh) * | 2024-04-25 | 2025-01-10 | 华中农业大学 | 用于降血糖的蛋壳膜水解物、肽及其制备方法和应用 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3194732A (en) | 1960-10-03 | 1965-07-13 | Neuhauser Irene | Assisting healing of skin-denuded areas on the body with dried non-fibrous egg-shellmembrane products and compositions therefor |
| US6150090A (en) | 1986-01-09 | 2000-11-21 | Massachusetts Institute Of Technology | Nuclear factors associated with transcriptional regulation |
| US6617171B2 (en) * | 1998-02-27 | 2003-09-09 | The General Hospital Corporation | Methods for diagnosing and treating autoimmune disease |
| US20080063677A1 (en) * | 2004-03-10 | 2008-03-13 | New Life Resources, Llc | Therapeutic, nutraceutical and cosmetic applications for eggshell membrane and processed eggshell membrane preparations |
| US8580315B2 (en) * | 2004-03-10 | 2013-11-12 | Esm Technologies, Llc | Anti-inflammatory activity of eggshell membrane and processed eggshell membrane preparations |
| US8324237B2 (en) * | 2005-05-20 | 2012-12-04 | Smith Charles D | Methods for the treatment and prevention of inflammatory diseases |
| US8211477B2 (en) * | 2007-10-17 | 2012-07-03 | Biova, L.L.C. | Solubilized protein composition obtained from eggshell membrane |
| US20100179103A1 (en) * | 2008-07-21 | 2010-07-15 | Ketan Desai | Curcumin cyclodextrin combination for preventing or treating various diseases |
| JP6056064B2 (ja) * | 2013-11-29 | 2017-01-11 | 国立大学法人 東京大学 | 卵殻膜成分を含むインスリン抵抗性改善剤ならびにそれを用いた組成物 |
-
2015
- 2015-10-08 US US15/528,335 patent/US10328104B2/en active Active
- 2015-10-08 HU HUE15905957A patent/HUE060219T2/hu unknown
- 2015-10-08 AU AU2015411324A patent/AU2015411324B2/en active Active
- 2015-10-08 PL PL15905957.5T patent/PL3359170T3/pl unknown
- 2015-10-08 WO PCT/US2015/054742 patent/WO2017062016A1/en not_active Ceased
- 2015-10-08 MX MX2017007130A patent/MX391376B/es unknown
- 2015-10-08 CA CA2970101A patent/CA2970101A1/en active Pending
- 2015-10-08 RU RU2017130716A patent/RU2713656C2/ru active
- 2015-10-08 BR BR112017014304A patent/BR112017014304A2/pt not_active Application Discontinuation
- 2015-10-08 JP JP2017529084A patent/JP2018531212A/ja active Pending
- 2015-10-08 DK DK15905957.5T patent/DK3359170T3/da active
- 2015-10-08 CN CN201580076036.0A patent/CN107206029A/zh active Pending
- 2015-10-08 RS RS20220921A patent/RS63620B1/sr unknown
- 2015-10-08 ES ES15905957T patent/ES2927890T3/es active Active
- 2015-10-08 KR KR1020187008834A patent/KR20180063091A/ko not_active Withdrawn
- 2015-10-08 EP EP15905957.5A patent/EP3359170B1/en active Active
-
2019
- 2019-06-06 US US16/433,683 patent/US11020437B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| WO2017062016A1 (en) | 2017-04-13 |
| EP3359170A1 (en) | 2018-08-15 |
| US20190365824A1 (en) | 2019-12-05 |
| US10328104B2 (en) | 2019-06-25 |
| CA2970101A1 (en) | 2017-04-13 |
| CN107206029A (zh) | 2017-09-26 |
| ES2927890T3 (es) | 2022-11-11 |
| RU2713656C2 (ru) | 2020-02-06 |
| RU2017130716A3 (es) | 2019-05-06 |
| RS63620B1 (sr) | 2022-10-31 |
| MX2017007130A (es) | 2018-01-30 |
| BR112017014304A2 (pt) | 2018-03-06 |
| DK3359170T3 (da) | 2022-10-10 |
| AU2015411324B2 (en) | 2023-06-15 |
| AU2015411324A1 (en) | 2018-03-22 |
| KR20180063091A (ko) | 2018-06-11 |
| US11020437B2 (en) | 2021-06-01 |
| US20180339002A1 (en) | 2018-11-29 |
| EP3359170A4 (en) | 2019-05-01 |
| RU2017130716A (ru) | 2019-02-28 |
| PL3359170T3 (pl) | 2022-11-07 |
| EP3359170B1 (en) | 2022-09-21 |
| HUE060219T2 (hu) | 2023-02-28 |
| JP2018531212A (ja) | 2018-10-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX391850B (es) | Compuestos para usarse en el tratamiento o mejoramiento de la enfermedad de huntington | |
| EA201790142A1 (ru) | Лечение лейкоза ингибиторами гистондеацетилазы | |
| MX2023007212A (es) | Formulaciones de pulverizacion de epinefrina. | |
| MX2017010982A (es) | Uso de pridopidina para mejorar la funcion cognitiva y para tratamiento de enfermedad de alzheimer. | |
| BR112015009948A8 (pt) | Antagonistas de ativina-actrii, usos dos mesmos para tratamento de doenças ósseas e outros distúrbios e método para monitorar a eficácia do tratamento ou prevenção de uma doença óssea e outros distúrbios | |
| CL2017002825A1 (es) | Formulaciones de tpp1 y métodos para tratar la enfermedad de cln2 | |
| PE20190338A1 (es) | Metodos de tratamiento de trastornos del desarrollo con gaboxadol | |
| AR083395A1 (es) | Derivado peptidico nmu (neuromedina u) con elevado efecto anorectico | |
| MX2015013948A (es) | Composicion farmaceutica, metodos para tratamiento y sus usos. | |
| MX2016014564A (es) | Vacuna contra la acinetobacter baumannii obtenida a partir de componentes celulares carentes de lipopolisacarido. | |
| RU2017116973A (ru) | Способы применения и композиции нейрегулинов для предотвращения, лечения или замедления сердечной недостаточности с сохраненной фракцией выброса | |
| GT201600084A (es) | (aza) piridopirazolopirimidinonas e indazolopirimidinonas y su uso | |
| EA201891440A1 (ru) | Составы/композиции, содержащие ингибитор btk | |
| EA201891664A1 (ru) | Составы/композиции, содержащие ингибитор btk | |
| MX387658B (es) | Métodos para tratar y/o prevenir queratosis actínica. | |
| MX2017011499A (es) | Combinaciones de dosis fija y formulaciones que comprenden ácido 8-hidroxi-2,2,14,14 tetrametilpentadecanodioico (etc1002) y ezetimiba y métodos para tratar o reducir el riesgo de enfermedad cardiovascular. | |
| EA201692111A1 (ru) | Фармацевтические композиции, содержащие данириксин, для лечения инфекционных заболеваний | |
| MX2020007462A (es) | Metodos de tratamiento de enfermedades inflamatorias cronicas. | |
| MX383462B (es) | Pridopidina para el tratamiento de las discinesias inducidas por fármacos | |
| MX391376B (es) | Composiciones de la membrana de la cáscara del huevo para usarse en el tratamiento de la cadena ligera kappa del factor nuclear de las células b activadas (nf-kb) en un organismo hospedero. | |
| MX374458B (es) | Compuestos de triaminopirimidina útiles para evitar o tratar la malaria. | |
| EA202090164A1 (ru) | Изотретиноиновые перорально-слизистые композиции и способы их применения | |
| MX2017002818A (es) | Composiciones topicas de pterostilbeno para utilizarse en el tratamiento de la perdida inducida por uv de la funcion de barrera en la piel. | |
| EA201791525A2 (ru) | Соединения для лечения блокады ремиелинизации при заболеваниях, связанных с экспрессией белка оболочки herv-w | |
| MX2018002298A (es) | Metodos de uso de interleucina 10 para el tratamiento de enfermedades y trastornos. |